122 related articles for article (PubMed ID: 38269469)
1. The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma.
Guare EG; Hale CM; Sivik J; Lehman E; Inoue Y; Rakszawski K; Songdej N; Nickolich M; Zheng H; Naik S; Claxton D; Rybka W; Hohl R; Mineishi S; Minagawa K; Paules CI
Transpl Infect Dis; 2024 Apr; 26(2):e14241. PubMed ID: 38269469
[TBL] [Abstract][Full Text] [Related]
2. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma.
Sivik JM; Davidson J; Hale CM; Drabick JJ; Talamo G
Support Care Cancer; 2018 Sep; 26(9):3055-3061. PubMed ID: 29564621
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look.
Maakaron JE; Liscynesky C; Boghdadly ZE; Huang Y; Agyeman A; Brammer J; Penza S; Efebera Y; Benson D; Rosko A; William B; Jaglowski SM
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e198-e201. PubMed ID: 32304873
[TBL] [Abstract][Full Text] [Related]
4. Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients.
Rodríguez-Lobato LG; Martínez-Roca A; Moreno DF; Gutiérrez-García G; Suárez-Lledó M; Rovira M; Martínez C; Rosiñol L; Almeida Jorge AS; Pedraza A; Cardozo C; Puerta-Alcalde P; Garcia-Vidal C; Marín P; Cid J; Lozano M; Gallego C; Hernando A; Segura S; Urbano-Ispizua Á; Fernández-Avilés F
Leuk Lymphoma; 2020 Jul; 61(7):1565-1574. PubMed ID: 32208787
[TBL] [Abstract][Full Text] [Related]
5. Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis.
Miles-Jay A; Butler-Wu S; Rowhani-Rahbar A; Pergam SA
Biol Blood Marrow Transplant; 2015 Mar; 21(3):539-45. PubMed ID: 25498393
[TBL] [Abstract][Full Text] [Related]
6. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Satlin MJ; Vardhana S; Soave R; Shore TB; Mark TM; Jacobs SE; Walsh TJ; Gergis U
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1808-14. PubMed ID: 26150022
[TBL] [Abstract][Full Text] [Related]
7. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
[TBL] [Abstract][Full Text] [Related]
8. Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma.
Kim JH; Goulston C; Zangari M; Tricot G; Boyer MW; Hanson KE
Transpl Infect Dis; 2014 Jun; 16(3):421-9. PubMed ID: 24797543
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the rates of Clostridium difficile and bacteremia after delaying fluoroquinolone prophylaxis from day 0 to day +3 post autologous stem cell transplantation.
Koseck K; Steinberg A; Caliendo G; Meyer J; Kim SS
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28456140
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on levofloxacin prophylaxis.
Signorelli J; Zimmer A; Liewer S; Shostrom VK; Freifeld A
Transpl Infect Dis; 2020 Apr; 22(2):e13225. PubMed ID: 31785022
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.
Modi D; Jang H; Kim S; Surapaneni M; Sankar K; Deol A; Ayash L; Bhutani D; Lum LG; Ratanatharathorn V; Manasa R; Mellert K; Chandrasekar P; Uberti JP
Support Care Cancer; 2017 Aug; 25(8):2593-2601. PubMed ID: 28365897
[TBL] [Abstract][Full Text] [Related]
12. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.
Seo SK; Xiao K; Huang YT; Jongwutiwes U; Chung D; Maloy M; Giralt S; Barker JN; Jakubowski AA; Papanicolaou GA
J Infect; 2014 Oct; 69(4):341-351. PubMed ID: 24931578
[TBL] [Abstract][Full Text] [Related]
13. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J; Madero-Marroquin R; Zubizarreta N; Moshier E; Tremblay D; Coltoff A; Lancman G; Fuller R; Rana M; Mascarenhas J; Jacobs SE
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):903-911. PubMed ID: 36109322
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.
Simondsen KA; Reed MP; Mably MS; Zhang Y; Longo WL
J Oncol Pharm Pract; 2013 Dec; 19(4):291-7. PubMed ID: 23184539
[TBL] [Abstract][Full Text] [Related]
15. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
16. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever.
Rodríguez-Lobato LG; Martínez-Roca A; Castaño-Díez S; Palomino-Mosquera A; Gutiérrez-García G; Pedraza A; Suárez-Lledó M; Rovira M; Martínez C; Fernández de Larrea C; Cibeira MT; Rosiñol L; Lozano E; Marín P; Cid J; Lozano M; Moreno-Castaño AB; Palomo M; Díaz-Ricart M; Gallego C; Hernando A; Segura S; Carreras E; Urbano-Ispizua Á; Bladé J; Fernández-Avilés F
PLoS One; 2020; 15(11):e0241778. PubMed ID: 33147257
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
Ziegler M; Landsburg D; Pegues D; Bilker W; Gilmar C; Kucharczuk C; Gorman T; Bink K; Moore A; Fitzpatrick R; Stadtmauer EA; Mangan P; Kraus K; Han JH
Biol Blood Marrow Transplant; 2019 May; 25(5):1004-1010. PubMed ID: 30481595
[TBL] [Abstract][Full Text] [Related]
18. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
19. Oral Ciprofloxacin Prophylaxis in Patients Undergoing High DoseTherapy and Autologous Hematopoietic Stem Cell Transplantation.
Tabarraee M; Tavakoli-Ardakani M; Mehdizadeh M; Ghadiani M; Rezvani H; Hajifathali A; Khamsi S
Iran J Pharm Res; 2016; 15(Suppl):159-163. PubMed ID: 28228813
[TBL] [Abstract][Full Text] [Related]
20. Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance.
Nair A; Kaundal S; Kasudhan KS; Chopra M; Singh C; Jandial A; Jain A; Prakash G; Khadwal A; Angrup A; Patil A; Ray P; Malhotra P; P Lad D
Blood Cell Ther; 2023 May; 6(2):61-65. PubMed ID: 37346770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
